Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 See also  




2 References  




3 External links  













MIN-117







Add links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

MIN-117
Clinical data
Other namesWF-516
Identifiers

  • (2S)-1-[4-(3,4-Dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol[1]

CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC25H25Cl2N3O
Molar mass454.40 g·mol−1
3D model (JSmol)

  • CC1=NN=C(O1)C2=CC3=C(O2)C=CC=C3OC[C@H](CN4CCC(CC4)C5=CC(=C(C=C5)Cl)Cl)O

  • InChI=1S/C25H25Cl2N3O4/c1-15-28-29-25(33-15)24-12-19-22(3-2-4-23(19)34-24)32-14-18(31)13-30-9-7-16(8-10-30)17-5-6-20(26)21(27)11-17/h2-6,11-12,16,18,31H,7-10,13-14H2,1H3/t18-/m0/s1

  • Key:XIYDIPLATGRHEC-SFHVURJKSA-N

MIN-117 (known formerly as WF-516) is an investigational antidepressant which is under development by Minerva Neurosciences for the clinical treatment of major depressive disorder (MDD).[2][3][4] It is described as a 5-HT1A and 5-HT2A receptor antagonist and inhibitorofserotonin and dopamine reuptake,[4][5][6] and is also reported to possess affinity for the α1A- and α1B-adrenergic receptors.[4][6] As of May 2015, MIN-117 is in phase II clinical trials for MDD.[3] In December 2019, Minerva announced that MIN-117 was no longer in clinical development for MDD after disappointing results in a phase IIb trial.[7]

See also[edit]

References[edit]

  1. ^ Saijo T, Maeda J, Okauchi T, Maeda J, Morio Y, Kuwahara Y, et al. (2012). "Presynaptic selectivity of a ligand for serotonin 1A receptors revealed by in vivo PET assays of rat brain". PLOS ONE. 7 (8): e42589. Bibcode:2012PLoSO...742589S. doi:10.1371/journal.pone.0042589. PMC 3413639. PMID 22880045.
  • ^ "Minerva Neuroscience". Retrieved 2015-05-19.
  • ^ a b Minerva Neurosciences (2015). "Minerva Neurosciences Reports First Quarter 2015 Financial Results and Other Key Business Updates" (Press release). GlobalNewswire. Retrieved 2015-05-19.
  • ^ a b c Minerva Neurosciences. "Investor Presentation March 2015" (PDF). Archived from the original (PDF) on 2015-05-20. Retrieved 2015-05-19.
  • ^ "Company Profile for Minerva Neurosciences Inc". Reuters. Archived from the original on 2015-05-20. Retrieved 2015-05-19.
  • ^ a b Dion D (2014). "Some Nerves Surrounding Minerva Neurosciences IPO". Seeking Alpha. Retrieved 2015-05-19.
  • ^ "Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder". BioSpace. Retrieved 2020-07-28.

    • External links[edit]

    Stub icon

    This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=MIN-117&oldid=1199550872"
    Categories: 
    ●4-Phenylpiperidines
     ●5-HT1A antagonists
     ●5-HT2A antagonists
     ●Experimental antidepressants
     ●Benzofuran ethers at the benzene ring
     ●Serotonin–dopamine reuptake inhibitors
     ●Nervous system drug stubs
     Hidden categories: 
    ●Articles with short description
     ●Short description matches Wikidata
     ●Articles without EBI source
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Drugs missing an ATC code
     ●Drugs with no legal status
     ●Articles containing unverified chemical infoboxes
     ●All stub articles
      


    ●This page was last edited on 27 January 2024, at 09:56 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki